ASH 2022 | The importance of CD47 as a target in MDS and AML
Naval Daver
• 12 Dec 2022
In this video, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the importance of CD47 as a target in various hematological malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and lymphoma. Dr Daver also comments on current trials investigating the impact of CD47 inhibition. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
